CD19 Directed Therapy Debate: Blinatumomab vs. CD19 Chimeric Antigen Receptor T-cells (CAR-T) for Acute Lymphoblastic Leukemia (ALL) (BCOP Session)
- Registration Closed
Title: CD19 Directed Therapy Debate: Blinatumomab vs. CD19 Chimeric Antigen Receptor T-cells (CAR-T) for Acute Lymphoblastic Leukemia (ALL)
Speakers: Anthony J. Perissinotti, PharmD, BCOP and Bernard Lawrence Marini, PharmD, BCOP
This session was originally presented at the 2022 Tandem Meetings Pharmacist Conference.
- Review key background information in the treatment of acute lymphoblastic leukemia (ALL)
- Appraise the literature surrounding the use of blinatumomab and chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of ALL
- Defend the use of either blinatumomab or CAR-T given a patient scenario
- Compare and contrast major toxicities of blinatumomab and CAR-T, including financial toxicity
This session has been accredited for 1 hour of BCOP Credit by HOPA. In order to claim BCOP credit, learners must view the presentation in its entirety and pass the quiz with a minimum score of 80%. You will only have two attempts to pass the quiz.
|Access Date||Quiz Result||Score||Actions|